Several recent studies have demonstrated that timely and appropriate use of structured SMBG data improve glycemic control and reduce diabetes-related distress in both insulin-treated and noninsulin-treated diabetes.1–4,33,34 However, it is also well-documented that obtaining an accurate and complete BG data from traditional patient logbooks is problematic5–7 and inadequacy of data may contribute to clinician inertia in intensifying diabetes therapy.8–12. This evidence concerns the gene INS and diabetes mellitus.